Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$1.15 USD
+0.02 (1.77%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.19 +0.04 (3.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Lyell Immunopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 85 | 11 | 8 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 85 | 11 | 8 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 247 | 272 | 225 | 220 | 103 |
Income After Depreciation & Amortization | -247 | -187 | -215 | -212 | -102 |
Non-Operating Income | 12 | 4 | -35 | 7 | -27 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -235 | -183 | -250 | -204 | -129 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -235 | -183 | -250 | -204 | -129 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -235 | -183 | -250 | -204 | -129 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -236 | -170 | -199 | -207 | -102 |
Depreciation & Amortization (Cash Flow) | 11 | 17 | 16 | 5 | 0 |
Income After Depreciation & Amortization | -247 | -187 | -215 | -212 | -102 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 250.98 | 247.08 | 135.92 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.93 | -0.74 | -1.84 | NA | NA |
Diluted Net EPS (GAAP) | -0.93 | -0.74 | -1.84 | NA | NA |
Fiscal Year end for Lyell Immunopharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.01 | 0.00 | 0.01 | 0.03 | 0.03 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.01 | 0.00 | 0.01 | 0.03 | 0.03 |
SG&A, R&D, and Dept/Amort Expenses | 51.54 | 55.57 | 59.53 | 59.07 | 65.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | -51.53 | -55.57 | -59.52 | -59.04 | -65.90 |
Non-Operating Income | 5.72 | -5.09 | 6.58 | 8.19 | 2.02 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -45.81 | -60.67 | -52.93 | -50.85 | -63.89 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -45.81 | -60.67 | -52.93 | -50.85 | -63.89 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -45.81 | -60.67 | -52.93 | -50.85 | -63.89 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 255.40 | 254.25 | 250.98 | 251.32 | 250.20 |
Diluted EPS Before Non-Recurring Items | -0.18 | -0.24 | -0.20 | -0.20 | -0.26 |
Diluted Net EPS (GAAP) | -0.18 | -0.24 | -0.20 | -0.20 | -0.26 |